BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hogan MP, Goldman DA, Dashevsky B, Riedl CC, Gönen M, Osborne JR, Jochelson M, Hudis C, Morrow M, Ulaner GA. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma. J Nucl Med 2015;56:1674-80. [PMID: 26294295 DOI: 10.2967/jnumed.115.161455] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
Number Citing Articles
1 Kawaguchi S, Tamura N, Tanaka K, Kobayashi Y, Sato J, Kinowaki K, Shiiba M, Ishihara M, Kawabata H. Clinical prediction model based on 18F-FDG PET/CT plus contrast-enhanced MRI for axillary lymph node macrometastasis. Front Oncol 2022;12:989650. [DOI: 10.3389/fonc.2022.989650] [Reference Citation Analysis]
2 Wong K, Sheehan-dare G, Nguyen A, Ho B, Liu V, Lee J, Brown L, Dear R, Chan L, Sharma S, Malaroda A, Smith I, Lim E, Emmett L. 64Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial. Pharmaceuticals 2022;15:772. [DOI: 10.3390/ph15070772] [Reference Citation Analysis]
3 Bhaludin BN, Tunariu N, Senthivel N, Babiker A, Soneji ND, Hujairi N, Sharma B, McGrath SE, Okines AF, Ring AE, Messiou C, Downey K, Koh DM. Does the addition of whole-body MRI to routine imaging influence real-world treatment decisions in metastatic breast cancer? Cancer Imaging 2022;22:26. [PMID: 35672838 DOI: 10.1186/s40644-022-00464-4] [Reference Citation Analysis]
4 Groheux D. FDG-PET/CT for Primary Staging and Detection of Recurrence of Breast Cancer. Semin Nucl Med 2022:S0001-2998(22)00051-4. [PMID: 35636977 DOI: 10.1053/j.semnuclmed.2022.05.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Van Baelen K, Geukens T, Maetens M, Tjan – Heijnen V, Lord C, Linn S, Bidard F, Richard F, Yang W, Steele R, Pettitt S, Van Ongeval C, De Schepper M, Isnaldi E, Nevelsteen I, Smeets A, Punie K, Voorwerk L, Wildiers H, Floris G, Vincent-salomon A, Derksen P, Neven P, Senkus E, Sawyer E, Kok M, Desmedt C. Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. Annals of Oncology 2022. [DOI: 10.1016/j.annonc.2022.05.006] [Reference Citation Analysis]
6 Bhaludin BN, Tunariu N, Koh DM, Messiou C, Okines AF, McGrath SE, Ring AE, Parton MM, Sharma B, Gagliardi T, Allen SD, Pope R, Johnston SRD, Downey K. A review on the added value of whole-body MRI in metastatic lobular breast cancer. Eur Radiol 2022. [PMID: 35384456 DOI: 10.1007/s00330-022-08714-6] [Reference Citation Analysis]
7 Ulaner GA. 16α-18F-fluoro-17β-Fluoroestradiol (FES): Clinical Applications for Patients With Breast Cancer. Seminars in Nuclear Medicine 2022. [DOI: 10.1053/j.semnuclmed.2022.03.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Wong YM, Jagmohan P, Goh YG, Putti TC, Ow SGW, Thian YL, Pillay P. Infiltrative pattern of metastatic invasive lobular breast carcinoma in the abdomen: a pictorial review. Insights Imaging 2021;12:181. [PMID: 34894297 DOI: 10.1186/s13244-021-01120-4] [Reference Citation Analysis]
9 Mankoff DA, Sellmyer MA. PET of Fibroblast-Activation Protein for Breast Cancer Diagnosis and Staging. Radiology 2022;302:48-9. [PMID: 34636639 DOI: 10.1148/radiol.2021212098] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Fowler AM, Cho SY. PET Imaging for Breast Cancer. Radiol Clin North Am 2021;59:725-35. [PMID: 34392915 DOI: 10.1016/j.rcl.2021.05.004] [Reference Citation Analysis]
11 Naghavi-Behzad M, Oltmann HR, Alamdari TA, Bülow JL, Ljungstrøm L, Braad PE, Asmussen JT, Vogsen M, Kodahl AR, Gerke O, Hildebrandt MG. Clinical Impact of FDG-PET/CT Compared with CE-CT in Response Monitoring of Metastatic Breast Cancer. Cancers (Basel) 2021;13:4080. [PMID: 34439232 DOI: 10.3390/cancers13164080] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Pirasteh A, Lovrec P, Pedrosa I. Imaging and its Impact on Defining the Oligometastatic State. Semin Radiat Oncol 2021;31:186-99. [PMID: 34090645 DOI: 10.1016/j.semradonc.2021.03.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Bottoni G, Piccardo A, Fiz F, Siri G, Matteucci F, Rocca A, Nanni O, Monti M, Brain E, Alberini JL, Dib B, Sacchetti GM, Saggia C, Rossi V, Harbeck N, Wuerstlein R, Degenhardt T, DeCensi A, Rollandi GA, Gennari A. Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT. Eur J Radiol 2021;141:109821. [PMID: 34139575 DOI: 10.1016/j.ejrad.2021.109821] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
14 Groheux D, Hindie E. Breast cancer: initial workup and staging with FDG PET/CT. Clin Transl Imaging 2021;:1-11. [PMID: 33937141 DOI: 10.1007/s40336-021-00426-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
15 Wahl RL, Chareonthaitawee P, Clarke B, Drzezga A, Lindenberg L, Rahmim A, Thackeray J, Ulaner GA, Weber W, Zukotynski K, Sunderland J. Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy. J Nucl Med 2021;62:6-14. [PMID: 33334911 DOI: 10.2967/jnumed.120.253450] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Davidson T, Shehade N, Nissan E, Sklair-Levy M, Ben-Haim S, Barshack I, Zippel D, Halevy A, Chikman B. PET/CT in breast cancer staging is useful for evaluation of axillary lymph node and distant metastases. Surg Oncol 2021;38:101567. [PMID: 33866190 DOI: 10.1016/j.suronc.2021.101567] [Reference Citation Analysis]
17 Han S, Choi JY. Impact of 18F-FDG PET, PET/CT, and PET/MRI on Staging and Management as an Initial Staging Modality in Breast Cancer: A Systematic Review and Meta-analysis. Clin Nucl Med 2021;46:271-82. [PMID: 33651022 DOI: 10.1097/RLU.0000000000003502] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Ulaner GA, Jhaveri K, Chandarlapaty S, Hatzoglou V, Riedl CC, Lewis JS, Mauguen A. Head-to-Head Evaluation of 18F-FES and 18F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer. J Nucl Med 2021;62:326-31. [PMID: 32680923 DOI: 10.2967/jnumed.120.247882] [Cited by in Crossref: 5] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
19 Kurland BF, Wiggins JR, Coche A, Fontan C, Bouvet Y, Webner P, Divgi C, Linden HM. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications. Oncologist 2020;25:835-44. [PMID: 32374053 DOI: 10.1634/theoncologist.2019-0967] [Cited by in Crossref: 9] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
20 Arnaout A, Varela NP, Allarakhia M, Grimard L, Hey A, Lau J, Thain L, Eisen A. Baseline staging imaging for distant metastasis in women with stages I, II, and III breast cancer. Curr Oncol 2020;27:e123-45. [PMID: 32489262 DOI: 10.3747/co.27.6147] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Lee AY, Navarro R, Busby LP, Greenwood HI, Bucknor MD, Ray KM, Joe BN. Characterization of Metastatic Sternal Lesions on Dynamic Contrast-Enhanced Breast MRI in Women with Invasive Breast Cancer. Acad Radiol 2019;26:1358-62. [PMID: 30527457 DOI: 10.1016/j.acra.2018.11.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Ulaner GA. PET/CT for Patients With Breast Cancer: Where Is the Clinical Impact? American Journal of Roentgenology 2019;213:254-65. [DOI: 10.2214/ajr.19.21177] [Cited by in Crossref: 17] [Cited by in F6Publishing: 29] [Article Influence: 5.7] [Reference Citation Analysis]
23 Ulaner GA, Schuster DM. Amino Acid Metabolism as a Target for Breast Cancer Imaging. PET Clin 2018;13:437-44. [PMID: 30100081 DOI: 10.1016/j.cpet.2018.02.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
24 Iagaru A, Minamimoto R. Nuclear Medicine Imaging Techniques for Detection of Skeletal Metastases in Breast Cancer. PET Clin 2018;13:383-93. [PMID: 30100077 DOI: 10.1016/j.cpet.2018.02.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
25 Ulaner GA, Juarez J, Riedl CC, Goldman DA. 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Breast Cancer in Men. J Nucl Med 2019;60:472-7. [PMID: 30237211 DOI: 10.2967/jnumed.118.217836] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
26 Chakraborty D, Basu S, Ulaner GA, Alavi A, Kumar R. Diagnostic Role of Fluorodeoxyglucose PET in Breast Cancer. PET Clinics 2018;13:355-61. [DOI: 10.1016/j.cpet.2018.02.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
27 Du T, Zhu L, Levine KM, Tasdemir N, Lee AV, Vignali DAA, Houten BV, Tseng GC, Oesterreich S. Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism. Sci Rep 2018;8:7205. [PMID: 29739984 DOI: 10.1038/s41598-018-25357-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
28 Provenzano E, Ulaner GA, Chin SF. Molecular Classification of Breast Cancer. PET Clin 2018;13:325-38. [PMID: 30100073 DOI: 10.1016/j.cpet.2018.02.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 43] [Article Influence: 7.3] [Reference Citation Analysis]
29 Wibmer AG, Hricak H, Ulaner GA, Weber W. Trends in oncologic hybrid imaging. Eur J Hybrid Imaging 2018;2:1. [PMID: 29782605 DOI: 10.1186/s41824-017-0019-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
30 Ege Aktas G, Taştekin E, Sarikaya A. Assessment of biological and clinical aggressiveness of invasive ductal breast cancer using baseline 18F-FDG PET/CT-derived volumetric parameters. Nuclear Medicine Communications 2018;39:83-93. [DOI: 10.1097/mnm.0000000000000779] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
31 Caresia Aroztegui AP, García Vicente AM, Alvarez Ruiz S, Delgado Bolton RC, Orcajo Rincon J, Garcia Garzon JR, de Arcocha Torres M, Garcia-Velloso MJ; Oncology Task Force of the Spanish Society of Nuclear Medicine and Molecular Imaging. 18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging. Tumour Biol 2017;39:1010428317728285. [PMID: 29025377 DOI: 10.1177/1010428317728285] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 7.4] [Reference Citation Analysis]
32 Groheux D. FDG-PET/CT for systemic staging of patients with newly diagnosed breast cancer. Eur J Nucl Med Mol Imaging 2017;44:1417-9. [PMID: 28573331 DOI: 10.1007/s00259-017-3731-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
33 Vinh-Hung V, Everaert H, Farid K, Djassemi N, Baudin-Veronique J, Bougas S, Michailovich Y, Joachim-Contaret C, Cécilia-Joseph E, Verschraegen C, Nguyen NP. Preoperative [18]fluorodeoxyglucose-positron emission tomography/computed tomography in early stage breast cancer: Rates of distant metastases. World J Radiol 2017; 9(7): 312-320 [PMID: 28794827 DOI: 10.4329/wjr.v9.i7.312] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
34 Ulaner GA, Zindman AM, Zheng J, Kim TW, Healey JH. FDG PET/CT Assesses the Risk of Femoral Pathological Fractures in Patients With Metastatic Breast Cancer. Clin Nucl Med 2017;42:264-70. [PMID: 28166159 DOI: 10.1097/RLU.0000000000001580] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
35 Ulaner GA, Castillo R, Wills J, Gönen M, Goldman DA. 18F-FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer. Eur J Nucl Med Mol Imaging 2017;44:1420-7. [PMID: 28456837 DOI: 10.1007/s00259-017-3709-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
36 Ulaner GA, Mannelli L, Dunphy M. Value of second-opinion review of outside institution PET-CT examinations. Nucl Med Commun 2017;38:306-11. [PMID: 28291158 DOI: 10.1097/MNM.0000000000000647] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
37 Morgat C, Macgrogan G, Brouste V, Vélasco V, Sévenet N, Bonnefoi H, Fernandez P, Debled M, Hindié E. Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors. J Nucl Med 2017;58:1401-7. [DOI: 10.2967/jnumed.116.188011] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 7.4] [Reference Citation Analysis]
38 Horger M, Thaiss WM, Wiesinger B, Ditt H, Fritz J, Nikolaou K, Kloth C. Longitudinal Computed Tomography Monitoring of Pelvic Bones in Patients With Breast Cancer Using Automated Bone Subtraction Software. Invest Radiol 2017;52:288-94. [DOI: 10.1097/rli.0000000000000343] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
39 Dong A, Wang Y, Lu J, Zuo C. Spectrum of the Breast Lesions With Increased 18F-FDG Uptake on PET/CT. Clin Nucl Med 2016;41:543-57. [PMID: 26975010 DOI: 10.1097/RLU.0000000000001203] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 4.6] [Reference Citation Analysis]
40 Ulaner GA, Goldman DA, Corben A, Lyashchenko SK, Gönen M, Lewis JS, Dickler M. Prospective Clinical Trial of 18F-Fluciclovine PET/CT for Determining the Response to Neoadjuvant Therapy in Invasive Ductal and Invasive Lobular Breast Cancers. J Nucl Med 2017;58:1037-42. [PMID: 27856630 DOI: 10.2967/jnumed.116.183335] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
41 Venema CM, Apollonio G, Hospers GA, Schröder CP, Dierckx RA, de Vries EF, Glaudemans AW. Recommendations and Technical Aspects of 16α-[18F]Fluoro-17β-Estradiol PET to Image the Estrogen Receptor In Vivo: The Groningen Experience. Clinical Nuclear Medicine 2016;41:844-51. [DOI: 10.1097/rlu.0000000000001347] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
42 Stoykow C, Erbes T, Maecke HR, Bulla S, Bartholomä M, Mayer S, Drendel V, Bronsert P, Werner M, Gitsch G, Weber WA, Stickeler E, Meyer PT. Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET. Theranostics 2016;6:1641-50. [PMID: 27446498 DOI: 10.7150/thno.14958] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 8.3] [Reference Citation Analysis]
43 Ulaner GA, Castillo R, Goldman DA, Wills J, Riedl CC, Pinker-Domenig K, Jochelson MS, Gönen M. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer. Eur J Nucl Med Mol Imaging 2016;43:1937-44. [PMID: 27129866 DOI: 10.1007/s00259-016-3402-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
44 Ulaner GA, Goldman DA, Gönen M, Pham H, Castillo R, Lyashchenko SK, Lewis JS, Dang C. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers. J Nucl Med 2016;57:1350-6. [PMID: 26940766 DOI: 10.2967/jnumed.115.170456] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]